New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
08:34 EDTIMMUImmunomedics' Epratuzumab in Lupus showed long-term efficacy and safety
Immunomedics announced that patients with moderate-to-severe lupus who had received continued cycles of epratuzumab therapy maintained improvements or further improved their lupus disease activity over a timeframe of approximately 4 years. Importantly, lower levels of median corticosteroid use were also maintained throughout the study. Results from this open-label, single-arm extension study of the Phase III ALLEVIATE trials were reported by clinical investigators at the 2012 American College of Rheumatology Annual Scientific Meeting in Washington DC. Immunomedics has licensed the rights to the development and commercialization of epratuzumab to UCB in all autoimmune diseases.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
15:31 EDTIMMUImmunomedics volatility elevated
Immunomedics July call option implied volatility is at 199, August is at 176, November is a 145; compared to its 52-week range of 53 to 198, suggesting large price movement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use